Genomic correlates of response to CTLA-4 blockade in metastatic melanoma-Reference-Cited by-同舟云学术

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Published:2015-10-09 Issue:6257 Volume:350 Page:207-211
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Van Allen Eliezer M.¹²³,Miao Diana¹²,Schilling Bastian⁴⁵,Shukla Sachet A.¹²,Blank Christian⁶,Zimmer Lisa⁴⁵,Sucker Antje⁴⁵,Hillen Uwe⁴⁵,Geukes Foppen Marnix H.⁶,Goldinger Simone M.⁷,Utikal Jochen⁸⁹,Hassel Jessica C.¹⁰,Weide Benjamin¹¹,Kaehler Katharina C.¹²,Loquai Carmen¹³,Mohr Peter¹⁴,Gutzmer Ralf¹⁵,Dummer Reinhard⁷,Gabriel Stacey²,Wu Catherine J.¹²,Schadendorf Dirk⁴⁵,Garraway Levi A.¹²³

Affiliation:

1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

2. Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

3. Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

4. Department of Dermatology, University Hospital, University Duisburg—Essen, 45147 Essen, Germany.

5. German Cancer Consortium(DKTK), 69121 Heidelberg, Germany.

6. Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.

7. Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland.

8. Skin Cancer Unit, German Cancer Research Center(DKTK), 69121 Heidelberg, Germany.

9. Department of Dermatology, Venerology, and Allergology, University Medical Center, Ruprecht-Karls University of Heidelberg, 68167 Mannheim, Germany.

10. Department of Dermatology, University Hospital, Ruprecht-Karls University of Heidelberg, 69120 Heidelberg, Germany.

11. Department of Dermatology, University Hospital Tübingen, 72076 Tübingen, Germany.

12. Department of Dermatology, University Hospital Kiel, 24105 Kiel, Germany.

13. Department of Dermatology, University Medical Center, 55131 Mainz, Germany.

14. Department of Dermatology, Elbe-Kliniken, 21614 Buxtehude, Germany.

15. Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, 30625 Hannover, Germany.

Abstract

Is cancer immunotherapy a private affair? Immune checkpoint blockade, a relatively new cancer treatment, substantially extends the survival of a subset of patients. Previous work has shown that patients whose tumors harbor the largest number of mutations—and thus produce a large number of “neoantigens” recognized as foreign by the immune system—are most likely to benefit. Expanding on these earlier studies, Van Allen et al. studied over 100 patients with melanoma and found a similar correlation (see the Perspective by Gubin and Schreiber). There was no evidence, however, that specific neoantigen sequences were shared by patients who responded. Science , this issue p. 207 , see also p. 158

Funder

NIH

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference40 articles.

1. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

3. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

4. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

5. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Cited by 2140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis;Computational and Structural Biotechnology Journal;2024-12

2. Cell-cell communication network-based interpretable machine learning predicts cancer patient response to immune checkpoint inhibitors;Science Advances;2024-02-02

3. Immunotherapy for lung cancer;Pathology - Research and Practice;2024-02

4. Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients;Frontiers in Immunology;2024-01-29

5. Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma;Cancer Immunology, Immunotherapy;2024-01-27